vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and FLYEXCLUSIVE INC. (FLYX). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $92.1M, roughly 2.0× FLYEXCLUSIVE INC.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -4.6%, a 18.0% gap on every dollar of revenue. On growth, FLYEXCLUSIVE INC. posted the faster year-over-year revenue change (19.8% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-11.0M). Over the past eight quarters, FLYEXCLUSIVE INC.'s revenue compounded faster (21.9% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
FLYEXCLUSIVE INC. is a U.S.-headquartered private aviation services provider that offers private jet charter, aircraft management, maintenance repair, and fractional ownership programs. It primarily serves high-net-worth individuals, corporate clients, and government entities across North America, delivering personalized on-demand air travel solutions prioritizing safety and convenience.
AMPH vs FLYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $92.1M |
| Net Profit | $24.4M | $-4.3M |
| Gross Margin | 46.8% | 13.7% |
| Operating Margin | 19.4% | -12.3% |
| Net Margin | 13.3% | -4.6% |
| Revenue YoY | -1.8% | 19.8% |
| Net Profit YoY | -35.7% | 32.0% |
| EPS (diluted) | $0.51 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | — | ||
| Q3 25 | $191.8M | $92.1M | ||
| Q2 25 | $174.4M | $91.3M | ||
| Q1 25 | $170.5M | $88.1M | ||
| Q4 24 | $186.5M | — | ||
| Q3 24 | $191.2M | $76.9M | ||
| Q2 24 | $182.4M | $79.0M | ||
| Q1 24 | $171.8M | $80.0M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $-4.3M | ||
| Q2 25 | $31.0M | $-4.8M | ||
| Q1 25 | $25.3M | $-5.4M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $-6.3M | ||
| Q2 24 | $37.9M | $-5.2M | ||
| Q1 24 | $43.2M | $-5.8M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | 13.7% | ||
| Q2 25 | 49.6% | 15.0% | ||
| Q1 25 | 50.0% | 12.8% | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | 11.3% | ||
| Q2 24 | 52.2% | 7.9% | ||
| Q1 24 | 52.4% | 7.2% |
| Q4 25 | 19.4% | — | ||
| Q3 25 | 13.2% | -12.3% | ||
| Q2 25 | 24.2% | -13.5% | ||
| Q1 25 | 21.9% | -16.7% | ||
| Q4 24 | 24.2% | — | ||
| Q3 24 | 29.8% | -27.2% | ||
| Q2 24 | 30.3% | -27.6% | ||
| Q1 24 | 27.9% | -34.3% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | -4.6% | ||
| Q2 25 | 17.8% | -5.2% | ||
| Q1 25 | 14.8% | -6.2% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | -8.2% | ||
| Q2 24 | 20.8% | -6.5% | ||
| Q1 24 | 25.1% | -7.3% |
| Q4 25 | $0.51 | — | ||
| Q3 25 | $0.37 | $-0.25 | ||
| Q2 25 | $0.64 | $-0.26 | ||
| Q1 25 | $0.51 | $-0.30 | ||
| Q4 24 | $0.74 | — | ||
| Q3 24 | $0.78 | $-0.32 | ||
| Q2 24 | $0.73 | $-0.32 | ||
| Q1 24 | $0.81 | $-0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $18.7M |
| Total DebtLower is stronger | $608.7M | $123.9M |
| Stockholders' EquityBook value | $788.8M | $-434.2M |
| Total Assets | $1.6B | $448.1M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | $18.7M | ||
| Q2 25 | $231.8M | $15.8M | ||
| Q1 25 | $236.9M | $14.7M | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | $18.7M | ||
| Q2 24 | $217.8M | $9.3M | ||
| Q1 24 | $289.6M | $5.3M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | $123.9M | ||
| Q2 25 | $607.7M | $111.6M | ||
| Q1 25 | $603.9M | $121.6M | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | $197.9M | ||
| Q2 24 | $586.9M | $206.3M | ||
| Q1 24 | $594.0M | $209.4M |
| Q4 25 | $788.8M | — | ||
| Q3 25 | $776.7M | $-434.2M | ||
| Q2 25 | $757.5M | $-261.4M | ||
| Q1 25 | $751.3M | $-281.5M | ||
| Q4 24 | $732.3M | — | ||
| Q3 24 | $727.7M | $-192.0M | ||
| Q2 24 | $713.3M | $-149.7M | ||
| Q1 24 | $672.4M | $-149.5M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.7B | $448.1M | ||
| Q2 25 | $1.6B | $443.4M | ||
| Q1 25 | $1.6B | $466.8M | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | $1.5B | $487.1M | ||
| Q2 24 | $1.5B | $494.7M | ||
| Q1 24 | $1.6B | $524.1M |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-209.0K |
| Free Cash FlowOCF − Capex | $24.6M | $-11.0M |
| FCF MarginFCF / Revenue | 13.4% | -12.0% |
| Capex IntensityCapex / Revenue | 4.5% | 11.7% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-51.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | — | ||
| Q3 25 | $52.6M | $-209.0K | ||
| Q2 25 | $35.6M | $363.0K | ||
| Q1 25 | $35.1M | $-10.5M | ||
| Q4 24 | $29.0M | — | ||
| Q3 24 | $60.0M | $-12.3M | ||
| Q2 24 | $69.1M | $-16.2M | ||
| Q1 24 | $55.3M | $-26.0M |
| Q4 25 | $24.6M | — | ||
| Q3 25 | $47.2M | $-11.0M | ||
| Q2 25 | $25.0M | $353.0K | ||
| Q1 25 | $24.4M | $-14.6M | ||
| Q4 24 | $16.6M | — | ||
| Q3 24 | $46.2M | $-25.7M | ||
| Q2 24 | $63.1M | $-26.6M | ||
| Q1 24 | $46.5M | $-64.5M |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 24.6% | -12.0% | ||
| Q2 25 | 14.3% | 0.4% | ||
| Q1 25 | 14.3% | -16.5% | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 24.1% | -33.5% | ||
| Q2 24 | 34.6% | -33.7% | ||
| Q1 24 | 27.1% | -80.6% |
| Q4 25 | 4.5% | — | ||
| Q3 25 | 2.8% | 11.7% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 4.7% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.2% | 17.5% | ||
| Q2 24 | 3.3% | 13.2% | ||
| Q1 24 | 5.1% | 48.2% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FLYX
Segment breakdown not available.
